NCT03892096View on ClinicalTrials.gov

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

November 15, 2023

Study Completion Date

February 6, 2024

Conditions
Metastatic Non-Small Cell Lung CarcinomaMetastatic Colorectal CancerMetastatic Breast Cancer
Interventions
DIAGNOSTIC_TEST

Blood-based cell-free cfDNA qPCR assay

Up to 30mL of blood via venipuncture

Trial Locations (12)

11776

National Translational Research Group LLC, Port Jefferson Station

27518

Waverly Hematology Oncology, Cary

28732

Advent Health, Hendersonville

29605

Greenville Health System - Prisma Health, Greenville

31904

IACT Health, Columbus

68130

Nebraska Cancer Center, Omaha

70112

University Medical Center, New Orleans

70119

Southeast Louisiana Veterans Health Care System, New Orleans

72205

CARTI Cancer Center, Little Rock

80218

Rocky Mountain Cancer Centers, Denver

94086

Sutter Health - Palo Alto Medical Foundation, Sunnyvale

H3H 2R9

McGill University, Montreal

Sponsors

Lead Sponsor

Cadex Genomics
All Listed Sponsors
lead

Cadex Genomics

INDUSTRY